1. In Vivo

Genomics Squatter

Armed with a purification technology it uses to isolate human DNA from the much more abundant nonhuman DNA found in stool samples, Exact Sciences is taking already-known disease-associated genomics markers into the clinical diagnostics setting. With the May announcement of the availability of its first test, for a rare form of colorectal cancer, the company is gaining visibility and traction.

Undaunted by questions surrounding the power of genomics to impact drug and diagnostics development and the crush of companies rushing to reposition themselves as protein- not gene-focused, Exact Sciences Corp.(formerly Exact Laboratories Inc.) stubbornly insists on being known as an applied genomics company. The characterization is right on. The cancer diagnostics company does not seek to discover genes or disease-associated targets; rather, it takes already-known genomics discoveries into the clinical diagnostics setting. With the May announcement of the availability of its first test, the company is gaining visibility and traction.

What Exact brings to the table is a proprietary purification technology it uses to isolate human DNA from the much more abundant nonhuman DNA found in stool samples, based on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.